Drug Profile
Infliximab biosimilar - Merck & Co./Samsung Bioepis
Alternative Names: Flixabi; Infliximab - Samsung Bioepis; Infliximab-abda; RENFLEXIS; SB 2Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Samsung Bioepis
- Developer Merck & Co; Samsung Bioepis
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis